Morin, a flavonoid from moraceae, inhibits cancer cell adhesion to endothelial cells and EMT by down-regulating VCAM-1 and N-cadherin
- Authors
- Lee, J.-H.; Jin, H.; Lee, W.S.; Nagappan, A.; Choi, Y.H.; Kim, G.; Jung, J.-M.; Ryu, C.H.; Shin, S.C.; Hong, S.C.; Kim, H.J.
- Issue Date
- 2016
- Publisher
- Asian Pacific Organization for Cancer Prevention
- Keywords
- Adhesion; Breast cancer cells; downregulation; Metastasis; Morin; N-cadherinn; VCAM-1
- Citation
- Asian Pacific Journal of Cancer Prevention, v.17, no.7, pp 3071 - 3075
- Pages
- 5
- Indexed
- SCOPUS
- Journal Title
- Asian Pacific Journal of Cancer Prevention
- Volume
- 17
- Number
- 7
- Start Page
- 3071
- End Page
- 3075
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/16657
- ISSN
- 1513-7368
- Abstract
- Morin, a flavonoid found in figs and other Moraceae species, displays a variety of biological actions, exerting anti-oxidant, anti-inflammatory and anti-carcinogenic effects. Here, we investigated the anti-cancer activity of morin focusing on anti-adhesive influence. We performed experiments with MDA-MB-231 human breast cancer cells. Morin inhibited TNF-induced cancer cell adhesion to human umbilical vein endothelial cells (HUVECs) without showing any toxicity. It further inhibited the expression of VCAM-1 on MDA-MB-231 cells as well as HUVECs. Morin also decreased the expression of N-cadherin on MDA-MB-231 cells. In addition, there was apparent anti-metastatic activity in vivo. In conclusion, this study suggested that morin inhibits cancer cell adhesion to HUVECs by reducing VCAM-1, and EMT by targeting N-cadherin, and that it features anti-metastatic activity in vivo. Further investigation of possible anti-metastatic activity of morin against human breast cancer cells is warranted.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 수의과대학 > Department of Veterinary Medicine > Journal Articles
- College of Medicine > Department of Medicine > Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.